18F-ASIS

Osteosarcoma

Var2 PharmaceuticalsEarly Phase 1Active

C

38/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 81/ 100

Competitive context

36 Active assets in the Osteosarcoma cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE Milton S. Hershey Medical Center	Phase 2	BB
Irinotecan Milton S. Hershey Medical Center	Phase 2	B
Cyclophosphamide M.D. Anderson Cancer Center	Phase 2	B
ETOPOSIDE Eisai Limited	Phase 2	B
Nivolumab Instituto do Cancer do Estado de São Paulo	Phase 2	B

View all 50 →

Same molecule, other indications

18F-ASIS is also rated in:

Inflammatory Demyelinating DiseaseDormant

CCC

Indicative ·

53 / 100

Thymus NeoplasmsDormant

CCC

Indicative ·

53 / 100

Non-small Cell Lung CancerDormant

CCC

Indicative ·

50 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.